BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gaeta GB, Precone DF, Felaco FM, Bruno R, Spadaro A, Stornaiuolo G, Stanzione M, Ascione T, De Sena R, Campanone A. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther. 2002;16:1633-1639. [PMID: 12197842 DOI: 10.1046/j.1365-2036.2002.01331.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Mulhall BP, Younossi Z. Impact of Adherence on the Outcome of Antiviral Therapy for Chronic Hepatitis C. Journal of Clinical Gastroenterology 2005;39:S23-7. [DOI: 10.1097/01.mcg.0000145538.43865.72] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
2 Lashin AH, Shaheen YA, Metwally MA, El-Feky HM, Hegab MF, Abbas SM. Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin. Indian J Gastroenterol 2013;32:316-23. [PMID: 23715642 DOI: 10.1007/s12664-013-0336-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
3 Santos AED, Partovi N, Ford JE, Yoshida EM. Use of Hematopoietic Growth Factors as Adjuvant Therapy for Anemia and Neutropenia in the Treatment of Hepatitis C. Ann Pharmacother 2007;41:268-75. [DOI: 10.1345/aph.1h169] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Pellicano R, Craxì A, Almasio PL, Valenza M, Venezia G, Alberti A, Boccato S, Demelia L, Sorbello O, Picciotto A, Torre F, Ideo G, Cattaneo C, Berrutti M, Rizzetto M. Interferon β-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 2005; 11(29): 4484-4489 [PMID: 16052676 DOI: 10.3748/wjg.v11.i29.4484] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
5 Angelico M, Koehler-horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F. Peginterferon ??-2a and ribavirin versus peginterferon ??-2a monotherapy in early virological responders and peginterferon ??-2a and ribavirin versus peginterferon ??-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in na??ve patients with chronic hepatitis C: . European Journal of Gastroenterology & Hepatology 2008;20:680-7. [DOI: 10.1097/meg.0b013e3282f5196c] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Chapko MK, Dominitz JA. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. Aliment Pharmacol Ther 2006;24:1067-77. [DOI: 10.1111/j.1365-2036.2006.03089.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
7 Loustaud-Ratti V, Maynard M, Thevenon S, Pradat P, Rousseau A, Alain S, Deny P, Gagnieu MC, Tran A, Dao T, Silvain C, Lunel-Fabiani F, Picard N, Zublena I, Marquet P, Trepo C; RIBAJUSTE Group. Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin. Ther Drug Monit 2016;38:684-92. [PMID: 27559840 DOI: 10.1097/FTD.0000000000000332] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
8 Loustaud-Ratti V, Rousseau A, Marquet P, Denis F, Alain S. Ribavirin in chronic hepatitis C: past and future. Expert Rev Anti Infect Ther. 2009;7:249-253. [PMID: 19344238 DOI: 10.1586/eri.09.5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
9 Thevenot T, Di Martino V, Lunel-fabiani F, Vanlemmens C, Becker M, Bronowicki J, Bresson-hadni S, Miguet J. Traitements complémentaires de l’hépatite chronique virale C. Gastroentérologie Clinique et Biologique 2006;30:197-214. [DOI: 10.1016/s0399-8320(06)73154-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 Stickel F, Helbling B, Heim M, Geier A, Hirschi C, Terziroli B, Wehr K, De Gottardi A, Negro F, Gerlach T. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C: EPO and hepatitis C treatment. Journal of Viral Hepatitis 2012;19:77-87. [DOI: 10.1111/j.1365-2893.2011.01527.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
11 Farrell CP, Mercogliano G, Navarro VJ, Rossi S. Taribavirin: potential future in the treatment of hepatitis C. Future Virology 2011;6:147-55. [DOI: 10.2217/fvl.10.81] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Gish RG, Arora S, Rajender Reddy K, Nelson DR, O’brien C, Xu Y, Murphy B. Virological response and safety outcomes in therapy–naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study. Journal of Hepatology 2007;47:51-9. [DOI: 10.1016/j.jhep.2007.02.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
13 Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Volti GL, Galvano F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol 2011; 17(39): 4414-4420 [PMID: 22110268 DOI: 10.3748/wjg.v17.i39.4414] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
14 Loustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, Rousseau A, Carrier P. Ribavirin: Past, present and future. World J Hepatol 2016; 8(2): 123-130 [PMID: 26807208 DOI: 10.4254/wjh.v8.i2.123] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
15 Chen TM, Huang PT, Lin CH, Tsai MH, Lin LF, Liu CC, Ho KS, Tung JN. Feasibility of individualized treatment for hepatitis C patients in the real world. J Gastroenterol Hepatol 2010;25:61-9. [PMID: 19780879 DOI: 10.1111/j.1440-1746.2009.05946.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
16 Fredrick RT, Hassanein TI. Role of Growth Factors in the Treatment of Patients With HIV/HCV Coinfection and Patients With Recurrent Hepatitis C Following Liver Transplantation. Journal of Clinical Gastroenterology 2005;39:S14-22. [DOI: 10.1097/01.mcg.0000145537.66736.38] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
17 Lee LY, Tong CY, Wong T, Wilkinson M. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials: Hepatitis looks set to be a curable illness. International Journal of Clinical Practice 2012;66:342-55. [DOI: 10.1111/j.1742-1241.2012.02895.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
18 Sherman M, Cohen L, Cooper MA, Elkashab M, Feinman V, Fletcher D, Girgrah N, Heathcote J, Levstik M, McNaull WB, Wong D, Wong F, Yim C. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol 2006;20:479-85. [PMID: 16858501 DOI: 10.1155/2006/497059] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
19 Speičienė D, Kotovienė L, Mickevičius A, Liakina V, Valantinas J. EFFICACY OF TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION “UNDER REAL LIFE“ CONDITIONS. Medicinos teorija ir praktika 2014;21:23-32. [DOI: 10.15591/mtp.2015.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 van Soest H, Renooij W, van Erpecum KJ. Clinical and basal aspects of anemia during antiviral therapy for hepatitis C. Annals of Hepatology 2009;8:316-24. [DOI: 10.1016/s1665-2681(19)31744-2] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
21 Alavian S, Tabatabaei SV, Behnava B. Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis: Impact of erythropoietin on sustained virological response. Journal of Viral Hepatitis 2012;19:88-93. [DOI: 10.1111/j.1365-2893.2011.01532.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
22 Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004;126:1302-1311. [PMID: 15131791 DOI: 10.1053/j.gastro.2004.01.027] [Cited by in Crossref: 232] [Cited by in F6Publishing: 213] [Article Influence: 12.9] [Reference Citation Analysis]
23 Couri T, Aronsohn A. You Can't Have One Without the Other: Innovation and Ethical Dilemmas in Gastroenterology and Hepatology. Clin Gastroenterol Hepatol 2021;19:2015-9. [PMID: 32445954 DOI: 10.1016/j.cgh.2020.05.024] [Reference Citation Analysis]
24 Tinè F, Graviano D, Giannuoli G, Madonia S, Malizia G, Patti S, Fasola S, Cottone M, D'amico G. An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C. Pharmacoepidem Drug Safe 2010;19:1113-23. [DOI: 10.1002/pds.2025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology. 2007;45:806-816. [PMID: 17326207 DOI: 10.1002/hep.21565] [Cited by in Crossref: 128] [Cited by in F6Publishing: 130] [Article Influence: 8.5] [Reference Citation Analysis]
26 Vergara M, Gallach M, Dalmau B, Gil M, Miquel M, Rudi N, Gavarro A, Cebollero A, Masip M, Real J. [Results of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in clinical practice: a 5-year experience]. Gastroenterol Hepatol 2008;31:274-9. [PMID: 18448055 DOI: 10.1157/13119878] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Kim TH, Kim KA, Lim YS, Gwak G, Yoon J, Kang GH, Lee H. Prediction of Treatment Outcome in Chronic Hepatitis C Patients Based on Early Viral Dynamics during High-Dose Induction Interferon and Ribavirin Therapy. Intervirology 2005;48:230-8. [DOI: 10.1159/000084600] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
28 Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH; PROACTIVE Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004;40:1450-1458. [PMID: 15565613 DOI: 10.1002/hep.20482] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 6.1] [Reference Citation Analysis]
29 Ravi S, Nasiri-toosi M, Karimzadeh I, Khalili H, Ahadi-barzoki M, Dashti-khavidaki S. Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions. Expert Opinion on Drug Safety 2014;13:277-86. [DOI: 10.1517/14740338.2014.866091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
30 Benhamou Y. Anemia and clinical outcomes in hepatitis C. Journal of Hepatology 2007;47:7-9. [DOI: 10.1016/j.jhep.2007.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
31 Barut S, Karaer H, Oksuz E, Eken AG, Basak AN. Bell’s palsy and choreiform movements during peginterferon α and ribavirin therapy. World J Gastroenterol 2009; 15(29): 3694-3696 [PMID: 19653353 DOI: 10.3748/wjg.15.3694] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
32 Cash WJ, Patterson K, Callender ME, McDougall NI. Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients. J Viral Hepat 2010;17:269-73. [PMID: 19824945 DOI: 10.1111/j.1365-2893.2009.01177.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
33 Jarrett M, Cox P. Hepatitis C virus. Nurs Clin North Am 2004;39:219-29. [PMID: 15062738 DOI: 10.1016/j.cnur.2003.11.014] [Reference Citation Analysis]
34 Jung GS, Jeon JH, Choi YK, Jang SY, Park SY, Kim SW, Byun JK, Kim MK, Lee S, Shin EC, Lee IK, Kang YN, Park KG. Pyruvate dehydrogenase kinase regulates hepatitis C virus replication. Sci Rep 2016;6:30846. [PMID: 27471054 DOI: 10.1038/srep30846] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
35 Tandon P, Doucette K, Fassbender K, Vandermeer B, Durec T, Dryden DM. Granulocyte colony‐stimulating factor for hepatitis C therapy‐associated neutropenia: systematic review and economic evaluation. Journal of Viral Hepatitis 2011;18. [DOI: 10.1111/j.1365-2893.2011.01445.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
36 Kearney KR, Thornton JJ, Navarro VJ. Taribavirin for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotherapy 2008;9:3243-9. [DOI: 10.1517/14656560802594459] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
37 Larrey D, Couzigou P, Denis J. Hépatite chronique C : gestion des effets indésirables du traitement. Gastroentérologie Clinique et Biologique 2007;31:20-8. [DOI: 10.1016/s0399-8320(07)92559-2] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
38 Maieron A, Metz-Gercek S, Scherzer TM, Laferl H, Fischer G, Bischof M, Gschwantler M, Ferenci P. Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial. BMC Res Notes 2011;4:220. [PMID: 21714878 DOI: 10.1186/1756-0500-4-220] [Reference Citation Analysis]
39 Malaguarnera M, Vacante M, Bertino G, Neri S, Malaguarnera M, Gargante MP, Motta M, Lupo L, Chisari G, Bruno CM. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin. J Interferon Cytokine Res. 2011;31:653-659. [PMID: 21923249 DOI: 10.1089/jir.2011.0010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
40 Medeiros T, Salviato CM, do Rosário NF, Saraiva GDN, Esberard EBC, Almeida JR, Xavier AR, da Silva AA. Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience. Int J Clin Pharm 2017;39:1304-11. [PMID: 29079938 DOI: 10.1007/s11096-017-0552-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
41 Tsubota A, Fujise K, Namiki Y, Tada N. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol 2011; 17(4): 419-432 [PMID: 21274371 DOI: 10.3748/wjg.v17.i4.419] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
42 Kobayashi Y, Nishihama K, Miyachi H, Tanaka H, Yamamoto N, Iwasa M, Fukutome T, Shiraishi T, Takei Y. Acute septic shock during pegylated-interferon and ribavirin therapy in a patient with chronic hepatitis C who underwent aortic graft replacement. Clin J Gastroenterol 2011;4:179-83. [PMID: 26189351 DOI: 10.1007/s12328-011-0221-1] [Reference Citation Analysis]
43 Dulek DE, Fuhlbrigge RC, Tribble AC, Connelly JA, Loi MM, El Chebib H, Chandrakasan S, Otto WR, Diorio C, Keim G, Walkovich K, Jaggi P, Girotto JE, Yarbrough A, Behrens EM, Cron RQ, Bassiri H. Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. J Pediatric Infect Dis Soc 2020;9:716-37. [PMID: 32808988 DOI: 10.1093/jpids/piaa098] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
44 Lodato F, Azzaroli F, Brillanti S, Colecchia A, Tamé MR, Montagnani M, Muratori R, Giovanelli S, Feletti V, Bacchi Reggiani ML, Roda E, Mazzella G. Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study. J Viral Hepat 2005;12:536-42. [PMID: 16108771 DOI: 10.1111/j.1365-2893.2005.00638.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
45 Gul MH, Htun ZM, Shaukat N, Imran M, Khan A. Potential specific therapies in COVID-19. Ther Adv Respir Dis. 2020;14:1753466620926853. [PMID: 32436445 DOI: 10.1177/1753466620926853] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
46 Domingo P, Guardiola JM, Salazar J, Torres F, Mateo MG, Pacho C, Del Mar Gutierrez M, Lamarca K, Fontanet A, Martin J. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. Antimicrob Agents Chemother. 2012;56:2987-2993. [PMID: 22430973 DOI: 10.1128/aac.06473-11] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
47 Koirala J, Gandotra SD, Rao S, Sangwan G, Mushtaq A, Htwe TH, Adamski A, Blessman D, Khardori NM. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007;14:782-7. [DOI: 10.1111/j.1365-2893.2007.00870.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
48 Tanioka D, Iwasaki Y, Araki Y, Osawa T, Ikeda H, Ando M, Kobashi H, Sakaguchi K, Shiratori Y, Yamamoto K. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience. Liver International 2009;29:721-9. [DOI: 10.1111/j.1478-3231.2008.01964.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
49 Morisco F, Vitaglione P, Carbone A, Stingo S, Scarpati S, Ascione A, Marmo R, Fogliano V, Caporaso N. Tomato-based Functional Food as Interferon Adjuvant in HCV Eradication Therapy. Journal of Clinical Gastroenterology 2004;38:S118-20. [DOI: 10.1097/01.mcg.0000128935.48082.f9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
50 Loustaud-ratti V, Carrier P, Rousseau A, Maynard M, Babany G, Alain S, Trépo C, De Ledinghen V, Bourlière M, Pol S, Di Martino V, Zarski J, Pinta A, Sautereau D, Marquet P. Pharmacological exposure to ribavirin: A key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. Digestive and Liver Disease 2011;43:850-5. [DOI: 10.1016/j.dld.2011.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
51 Altraif IH, Sanai F, Babatin MA, Alalwan AA, Abdo AA, Alhamoudi W, Peedikayil M, Alghamdi H, Alsohaibani F, Alswat KA, Murtaza S, Alghamdi A, Altraif S, Aljumah A, Handoo FA, AlBekairy AM, Al-Ashgar HI, Alquaiz M, Alblawi MA, AlTamimi W, Loustaud-Ratti V, Marquett P. Pharmacokinetics-Based Adjusted Versus Standard Dose of Ribavirin Does Not Improve Virologic Response Rates in Chronic Hepatitis C Genotype 4 Patients: A Randomized Controlled Trial. J Interferon Cytokine Res 2017;37:488-93. [PMID: 29135370 DOI: 10.1089/jir.2017.0054] [Reference Citation Analysis]
52 Wai CT, Wong ML, Ng S, Cheok A, Tan MH, Chua W, Mak B, Aung MO, Lim SG. Utility of the Health Belief Model in predicting compliance of screening in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2005;21:1255-1262. [PMID: 15882247 DOI: 10.1111/j.1365-2036.2005.02497.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 1.6] [Reference Citation Analysis]
53 Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, Shimoe T, Takaguchi K, Hashimoto N, Kobatake T. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology. 2006;43:54-63. [PMID: 16374855 DOI: 10.1002/hep.20984] [Cited by in Crossref: 115] [Cited by in F6Publishing: 101] [Article Influence: 7.2] [Reference Citation Analysis]
54 Henry DH, Slim J, Lamarca A, Bowers P, Leitz G; HIV/HCV Coinfection Natural History Study Group. Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection. AIDS Res Hum Retroviruses 2007;23:1-9. [PMID: 17263626 DOI: 10.1089/aid.2006.0082] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]